Which Is the Best Option for <scp>AxSpA</scp> Patients After First <scp>TNFi</scp> Failure: Switch to Secukinumab or Cycling With Other <scp>TNFi</scp> ?
In axSpA exposed to a TNFi, switching to a second TNFi has comparable effectiveness to switching to SEC. SEC may be a better option in patients who experienced primary failure of TNFi, whereas an alternative TNFi may be preferred in patients with higher CRP levels or Achilles enthesitis, or who are currently smoking.
Authors
- Özlem Kılıç (ORCID: https://orcid.org/0000-0001-9582-4376)
- Mehmet Nur Kaya (ORCID: https://orcid.org/0000-0003-4368-3078)
- Duygu Tecer (ORCID: https://orcid.org/0000-0002-8816-6181)
- Sedat Yılmaz (ORCID: https://orcid.org/0000-0002-4691-3417)
Institutions
- Sağlık Bilimleri Üniversitesi (TR)
Publication Details
- Journal
- International Journal of Rheumatic Diseases
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1111/1756-185x.70212
- Citations
- 1
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.67